ASCO

IFCT-1001 CHIVA trial: A phase II study of carboplatin (Ca) plus pemetrexed (P) followed by P maintenance, as first-line therapy for human immunodeficiency virus (HIV)-associated advanced non-squamous non-small-cell lung cancer (NS-NSCLC)

ASCO 2016 – Lung Cancer, ASCO

Conference Correspondent

Local consolidative therapy (LCT) to improve progression-free survival (PFS) in patients with oligometastatic non-small cell lung cancer (NSCLC) who receive induction systemic therapy (IST): Results of a multi-institutional phase II randomized study

ASCO 2016 – Lung Cancer, ASCO

Conference Correspondent

Nivolumab (nivo) vs docetaxel (doc) in patients (pts) with advanced NSCLC: CheckMate-017/057 2-y update and exploratory cytokine profile analyses

ASCO 2016 – Lung Cancer, ASCO

Conference Correspondent

Open-label, multicenter, randomized phase III trial of pemetrexed/carboplatin doublet vs pemetrexed singlet in chemotherapy-naïve elderly patients aged 70 or more with advanced non-squamous non–small-cell lung cancer and good performance status

ASCO 2016 – Lung Cancer, ASCO

Conference Correspondent

Pembrolizumab (pembro) plus chemotherapy as front-line therapy for advanced NSCLC: KEYNOTE-021 cohorts A-C

ASCO 2016 – Lung Cancer, ASCO

Conference Correspondent

Pooled analysis of venous thromboembolism (VTE) from four trials of necitumumab and chemotherapy for stage IV non-small cell lung cancer (NSCLC)

ASCO 2016 – Lung Cancer, ASCO

Conference Correspondent

Relationship between level of PD-L1 expression and outcomes in the KEYNOTE-010 study of pembrolizumab vs docetaxel for previously treated, PD-L1–positive NSCLC

ASCO 2016 – Lung Cancer, ASCO

Conference Correspondent

Response to tyrosine kinase inhibitors in advanced non–small-cell lung cancer with concomitant c-MET overexpression and EGFR mutation

ASCO 2016 – Lung Cancer, ASCO

Conference Correspondent

Safety and clinical activity of durvalumab (MEDI4736), an anti-PD-L1 antibody, in treatment-naïve patients with advanced non‒small-cell lung cancer

ASCO 2016 – Lung Cancer, ASCO

Conference Correspondent

Genetic Abnormality Pinpointed for Intensive Therapy in Wilms Tumor

By Phoebe Starr

ASCO 2015 Highlights, ASCO

July 2015, Vol 6, No 6

Chicago, IL—In children who are at risk for Wilms tumor, the presence of a rare genetic abnormality identifies children who can have a survival benefit from the augmentation or intensification of therapy. The abnormality—loss of heterozygosity (LOH) on chromosomes 1p and 16q (LOH 1p/16q)—is associated with worse prognosis in children with Wilms tumor.

Page 5 of 19

2
3
4
5
6
7
8